Clinical Trial Update: Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating pazopanib in combination with interferon alfa-2a in advanced renal cell carcinoma across Phase 1 and Phase 2, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon alfa-2a (interferon alfa-2a)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Advanced Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED